(Q57695969)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15694507%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15694507%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

8 January 2020

main subject

1 reference

1 reference

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15694507%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Ava John-Baptiste

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15694507%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Qilong Yi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15694507%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Andrea Doria

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15694507%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Paul Ritvo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15694507%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Samuel Friedman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15694507%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Robert S Remis

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15694507%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

English

0 references

publication date

1 February 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15694507%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15694507%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15694507%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15694507%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

1549-1558

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15694507%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology of hepatitis C

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Estimating future hepatitis C morbidity, mortality, and costs in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Development of a hepatitis C virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

The challenge of developing a vaccine against hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Primer on Medical Decision Analysis: Part 5—Working with Markov Processes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Markov models in medical decision making: a practical guide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Varicella vaccination in England and Wales: cost-utility analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Crucial factors that influence cost-effectiveness of universal hepatitis B immunization in India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Assessment of a universal, school-based hepatitis B vaccination program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Hepatitis A virus vaccination among injecting drug users: Do We have to change the vaccination schedule?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

High Compliance with a Hepatitis B Virus Vaccination Program among Intravenous Drug Users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Mortality Rates of Persons Entering Methadone Maintenance: A Seven-Year Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Mortality among problem drug users in Rome: an 18-year follow-up study, 1980-97.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Mortality of intravenous drug users in Rome: a cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Addict death rates during a four-year posttreatment follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

A multicentre study on the causes of death among Italian injecting drug users. AIDS has overtaken overdose as the principal cause of death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Impact of HIV infection on mortality in a cohort of injection drug users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

The distinction between cost and charges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

A comparison of two methods for estimating the technical costs of external beam radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Health-State Utilities and Quality of Life in Hepatitis C Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Utility scores for chronic conditions in a community-dwelling population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Economic methods for measuring the quality of life associated with HIV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Generalizability of valuations on health states collected with the EuroQolc-questionnaire.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Validity of Euroqol--a generic health status instrument--in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

A successful approach to immunizing men who have sex with men against hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

Mortality after blood transfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

inferred from DOI database lookup

7 January 2021

based on heuristic

Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

inferred from DOI database lookup

7 January 2021

based on heuristic

Impact of HIV infection on non-AIDS mortality among Italian injecting drug users

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.023

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2004.09.023

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15694507%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference